Oncolys BioPharma Inc. announced that it has received notice from Transposon Therapeutics Inc. ("Transposon"), licensee of OBP-601 (censavudine, TPN-101), that the first patient has been enrolled in the Phase IIa, Open Label study of patients with Aicardi-Goutieres Syndrome (AGS). The study will be conducted in multiple centers in Europe. In addition, Transposon has completed enrollment in a Phase IIa, double-blind, placebo-controlled study of TPN-101 in patients with Progressive Supranuclear Palsy (PSP) and as well as completed enrollment in a Phase II a, double-blind, placebo -controlled study of TPN- 101 in patients with Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD) who have the C9ORF72 repeat expansion mutation.

The OBP-601 development program is designed to establish proof-of-concept for treating neurodegenerative diseases with evidence for involvement of LINE-1 reverse transcriptase.